KDT 501

Drug Profile

KDT 501

Alternative Names: KDT501

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KinDex Pharmaceuticals
  • Class Anti-inflammatories; Antihyperglycaemics; Cyclopentanes; Insulin sensitisers; Small molecules
  • Mechanism of Action GPR120 protein stimulants; Inflammasome modulators; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation; Non-alcoholic steatohepatitis
  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 06 Sep 2017 Discontinued - Phase-II for Type-2 diabetes mellitus in USA (PO)
  • 06 Sep 2017 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) (KinDex Pharmaceuticals pipeline, September 2017)
  • 30 Sep 2015 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top